Non-specific neck pain Patients with cervical radiculopathy Immune system Cytokine Chronic pain Microglia Physiotherapy Manual Therapy
Conditions
Interventions
Patients with non-specific neck pain in study 2 who are allocated to the intervention group will receive a single highvelocity low-amplitude distraction manipulation at the cervico-thoracic region (C7
Sponsors
Ducht Society for Manual Therapy; VU Amsterdam; MSG Science Network
Eligibility
Inclusion criteria
Inclusion criteria: Persistent non-specific neck pain Inclusion: • Age between 18-65 years. • Minimal score of 40 on the Visual Pain Anaolgue Scale. • Persistent pain is defined as pain complaints longer than 6 weeks. • Can be classified as grade 1 or 2 non-specific neck pain. • Written informed consent of the subject.
Exclusion criteria
Exclusion criteria: Persistent non-specific neck pain A potential subject who meets any of the following criteria will be excluded from participation in this study: • Pregnancy or postpartum for 9 months • Contra-indications for phlebotomy (e.g. phlebitis) • Underwent treatment for current complaints for the last 6 weeks (e.g. physiotherapy, manual therapy, GP etc.) • Having diagnosed mental health disorders (e.g. depression) • Taken one of the following medication for the last 6 weeks: corticosteroids (e.g. prednisone), immunomodulatory medication (e.g. methotrexate, infliximab etc.) and the use of botox for the last 3 months. • Taken one of the following medication: NSAID’s (e.g. diclofenac, ibuprofen, naproxen etc.), Aspirin, Simvastatin (58) for the last two weeks. • Long distance flight (within 7 days), ongoing shift work and hippocampal damage. • Having one of the following medical diseases o Neurological disorders (e.g. MS, myelopathie, cervical stenosis etc.) o Traumatic disorders (e.g. cervical fracture, surgery in the neck area etc.) o Having a history of malignity o Rheumatic or inflammatory disorders (e.g. Spondylitis Ankylpoetica, Crohn disease, sarcoidosis, colitis ulcerous, rheumatic arthritis, COPD, spastic colon, psoriasis etc.) o Cardiac diseases (e.g. history of myocardial infarction, abnormal heart rhythms) o Allergic reaction or auto immune diseases (e.g. type 1 diabetic, hay fever) o Metabolic disorders (e.g. type 2 diabetic) o Endocrinology disorders (e.g. Cushing Syndrome) o Haematological disorders (e.g. clothing problem) o Psychological/psychiatric disorders (e.g. depression, current high stress, Alzheimer disease) o Physical trauma for the last six weeks o Having the flue
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes are the short-term (i.e., immediately and two-hours following the intervention) differences in interleukin-1ß (IL-1ß) and tumor necrosis factor-a (TNF-a) following in-vitro stimulation of whole blood cells. | — |
Secondary
| Measure | Time frame |
|---|---|
| Several additional neuroimmune responses will be quantified as secondary outcomes at various time points: - Ex-vivo inflammatory markers - In-vitro inflammatory markers - PBMC phenotyping - Overall inflammatory index, pro-inflammatory index, anti-inflammatory index and ratio pro/anti inflammatory index | — |
Contacts
Public ContactG.G.M. Scholten-Peeters
VU University Amsterdam
Outcome results
None listed